Targeting myeloid-derived suppressor cells for cancer therapy
The emergence and clinical application of immunotherapy is considered a promising breakthrough in cancer treatment. According to the literature, immune checkpoint blockade (ICB) has achieved positive clinical responses in different cancer types, although its clinical efficacy remains limited in some...
Guardado en:
Autores principales: | Hongchao Tang, Hao Li, Zhijun Sun |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
China Anti-Cancer Association
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/277836c16d664728bdeac45eeca03939 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Chronic stress promotes breast carcinoma metastasis by accumulating myeloid-derived suppressor cells through activating β-adrenergic signaling
por: Jiale an, et al.
Publicado: (2021) -
Role of myeloid-derived suppressor cells in viral respiratory infections; Hints for discovering therapeutic targets for COVID-19
por: Khadijeh Koushki, et al.
Publicado: (2021) -
Differentiation therapy for myeloid malignancies: beyond cytotoxicity
por: Ryan J. Stubbins, et al.
Publicado: (2021) -
Carbon ion radiotherapy boosts anti-tumour immune responses by inhibiting myeloid-derived suppressor cells in melanoma-bearing mice
por: Heng Zhou, et al.
Publicado: (2021) -
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia
por: Mayumi Sugita, et al.
Publicado: (2021)